China Healthcare Investment Medicine Pharmaceutical Shanghai Technology Venture Capital
Beyang Therapeutics Co., Ltd. has successfully closed an oversubscribed Series A financing round, raising nearly $30 million to advance global clinical development of differentiated pipelines. The round was co-led by Legend Capital and Shanghai Healthcare Capital, with participation from China Medical System Holdings Limited, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, and Harbor & Canton Capital. Existing investors Root Venture Partners and YuanBio Venture Capital also continued their support. The funding will be used to accelerate the technological iteration of Beyang’s ExCEED platform and advance key pipeline candidates. Founded in 2021, Beyang Therapeutics is led by a team with over…
News Timeline:
Track the development of this news story across the Internet.